Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia - Archive ouverte HAL Access content directly
Journal Articles Leukemia Research Year : 2016

Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Abstract

This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n = 11), both unfavorable (n = 2), but AID improved while MDS/CMML worsened (n = 8) and vice versa (n = 1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings
Fichier principal
Vignette du fichier
Efficacy of Azacitidine in Autoimmune and Inflammatory.pdf (244.84 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01278608 , version 1 (07-06-2016)

Identifiers

Cite

Jean-Baptiste Fraison, Arsène Mekinian, Eric Grignano, Jean-Emmanuel Kahn, Jean-Benoit Arlet, et al.. Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Leukemia Research, 2016, 43, pp.13-17. ⟨10.1016/j.leukres.2016.02.005⟩. ⟨hal-01278608⟩
605 View
1271 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More